Kornimate/medical-research-clean huggingface dataset:
endoscopic lung volume reduction after catheter-based cv measurement in patients with heterogeneous emphysema and complete interlobar fissures

Conditions: Heterogeneous Emphysema

Summary: this clinical trial evaluates the impact of catheter-based measurement of interloabr collateral ventilation prior to endoscopic lung volume reduction in patients with hetereogeneous emphysema and complete interlobar fissures in high resolution computed tomography.

50 patients (25 per center) with heterogeneous lung emphysema with indication for endoscopic lung volume reduction by valve implantation will be prospectively included in the study. heterogeneity of emphysema and fissure completeness of the relevant lobe will be proven from high resolution computed tomography (hrct) prior to enrolment in the study. fissure integrity will be analyzed by a core radiology. if fissure completeness is proved, patients will be enrolled in the study. all recruited patients will additionally receive a collateral ventilation measurement by using the chartis® pulmonary assement system during a flexible bronchoscopy. depending on the results of this measurement, patients are divided in two parallel arms: a: complete fissure integrity and low collateral ventilation (cv negative) b: complete fissure integrity and high collateral ventilation (cv positive) following the cv measurement, each patient will receive valve therapy.

Eligibility criteria:
inclusion criteria: * written informed consent * ability to understand the importance of adherence to study treatment and the study protocol and willing to follow all study requirements * severe lung emphysema (fev1\ 150%, tlc\>100%) * po2\>60 mmhg with 4l o2, pco2 \< 60 mmhg at rest * heterogeneous lung emphysema diagnosed with hrct and perfusion scintigraphy * confirmed heterogeneity by yacta® * disclosure of parallel channels through relevant interlobar fissures * age \> 30 years * stable copd without exacerbation 8 weeks prior to screening * dose of cortisone\< 20 mg prednisone or equivalent ocs * non-smoker or ex-smoker who stopped smoking for at least 4 months prior to the screening visit * current cohb \< 2,5% exclusion criteria: * bmi \< 18 mg/kg2 * significant bronchiectasis with sputum production of 4 tablespoons/day * 6-minute-walk distance \< 150 m * myocardial infarction within 6 weeks prior screening visit * decompensated heart failure * cardiomyopathy with moderate or severe restricted lvf * long-term medication with clopidogrel * status after lung resection (lobectomy/pneumonectomy) * existing pregnancy * female subjects of child-bearing potential without acceptable forms of contraception
factors associated with high mortality of gastric adenocarcinoma in thailand versus japan

Conditions: Risk Factor

Summary: the differences in patient's clinicopathological characteristic between high and low prevalence of gastric cancer region should be further examined to elucidate factors that associate with poor survival rate of patients with gastric cancer. therefore, this study aimed to evaluate characteristics of patients with gastric adenocarcinoma and factors associated with different outcome in thailand and japan to find a clue to improve patients' survival in low prevalence country such as thailand. this is a retrospective cohort study. it was conducted at king chulalongkorn memorial hospital, thailand and osaka medical center for cancer and cardiovascular disease, japan. eligible cases were selected by using standardized search protocols: formal computer searches of all patients seen at out-patient clinic and/or hospitalized for gastric cancer between 2010 and 2014.two physicians, who were informed the definition of each variable, individually reviewed chart of patients.


Eligibility criteria:
inclusion criteria: * all patients seen at out-patient clinic and/or hospitalized for gastric cancer between 2010 and 2014. exclusion criteria: * age \< 18 years * incomplete data * miss diagnosis of gastric adenocarcinoma * died from other causes (not related to gastric adenocarcinoma).

Keywords: gastric cancer thailand japan
compined sonopulmonary infection score and apache score in ricu patients with vap

Conditions: Respiratory Intensive Care Unit Patients With Ventilator Associated Pneumonia

Summary: aim of the study : 1. efficacy of sono pulmonary infection score in combination with apache score in early diagnosis of vap 2. assessment of prediction role of combined sips score and apache score of outcome of vap patient in ricu 3. assessments of role of ultrasonography in early diagnosis and follow up of vap

pneumonia is a bacterial, viral or fungal infection of the lungs, which causes the alveoli of the lungs to fill up with microorganisms, fluid and inflammatory cells, preventing the lungs from functioning effectively\[1\]. ventilator associated pneumonia (vap) is the most common and a leading cause of death in intensive care unit patient. ventilator associated pneumonia is caused by prolonged duration of mechanical ventilation ,and prolonged hospital stay, which increase hospital costs, possibly increase mortality rate, and increase antibiotic use in icu patients , early identification of vap is an important clinical goal to improve patient outcomes \[2\]. in recent year several scoring systems have been developed to evaluate the severity of illness and to predict the outcome, especially the mortality rate of intensive care unit patient, such as the clinical pulmonary infection score (cpis) or modified (cpis)the clinical pulmonary infection score (cpis) was developed to serves a tool to facilitate the diagnosis of ventilator-associated pneumonia (vap),the cpis is calculated on the basis of points assigned for various signs and symptoms of pneumonia (eg, fever and extent of oxygenation mpairment) ,a cpis has an average between 0-12\>6 some studies suggest that cpis \>6 may correlate with vap sonar is easy bedside test to diagnose pleural effusion, pneumonia pneumothorax , so recently lung ultrasonography (lus) incorporated in evaluation and diagnosis of vap in a new score called sono pulmonary infection score (spis) . the (spis), where is incorporated lus finding instead of cxr finding of cpis is assigned two points for ≥ one area of dynamic air bronchogram. one point was given for ≥ two sub-pleural consolidation or lobar consolidation areas or ≥ one sub-pleural, and ≥one lobar consolidationrecently (combination of spis with apache score in assessment of vap is under research ).

Eligibility criteria:
inclusion criteria: 1. age \>18 yrs 2. mechanically ventilated patients after first 48 hours of admission in ricu exclusion criteria: 1. age \<18 yrs 2. patients already diagnosed pneumonia 3. malignancy 4. patient refused participation in the study.
forodesine (bcx-1777) in treating patients with refractory stage iia, stage iib, stage iii, stage iva, or stage ivb cutaneous t-cell lymphoma

Conditions: Lymphoma

Summary: rationale: forodesine (bcx-1777) may stop the growth of cancer cells by blocking the enzymes necessary for their growth. purpose: phase i trial to study the effectiveness of bcx-1777 in treating patients who have refractory stage iia, stage iib, stage iii, stage iva, or stage ivb cutaneous t-cell lymphoma.

objectives: * determine the safety and efficacy of forodesine (bcx-1777) in patients with refractory stage iia-ivb cutaneous t-cell lymphoma. * determine the pharmacokinetics and pharmacodynamics of this drug in these patients. outline: this is an open-label, multicenter study. patients receive oral forodesine (bcx-1777) once daily on days 1-28. courses may be repeated in the absence of disease progression or unacceptable toxicity. patients are followed periodically. projected accrual: not specified.

Eligibility criteria:
disease characteristics: * histologically confirmed cutaneous t-cell lymphoma * refractory to prior treatment * stage iia, iib, iii, iva, or ivb disease * measurable disease patient characteristics: age * 18 and over performance status * ecog 0-2 life expectancy * at least 3 months hematopoietic * not specified hepatic * ast and/or alt ≤ 3 times upper limit of normal * hepatitis b and/or hepatitis c negative renal * creatinine clearance ≥ 40 ml/min immunologic * human t-cell lymphotrophic virus type i (htlv-i) negative * hiv negative * no active serious infection not controlled by antibiotics other * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * no known impaired absorption of the gastrointestinal tract * no other illness that would preclude study participation prior concurrent therapy: biologic therapy * not specified chemotherapy * more than 21 days since prior chemotherapy and recovered endocrine therapy * concurrent topical corticosteroids allowed provided patient remains on a stable dose radiotherapy * no concurrent radiotherapy surgery * not specified other * more than 30 days since prior investigational agents and recovered * no concurrent tanning bed use * no other concurrent therapy for cutaneous t-cell lymphoma

Keywords: recurrent cutaneous t-cell non-hodgkin lymphoma stage ii cutaneous t-cell non-hodgkin lymphoma stage iii cutaneous t-cell non-hodgkin lymphoma stage iv cutaneous t-cell non-hodgkin lymphoma recurrent mycosis fungoides/sezary syndrome stage ii mycosis fungoides/sezary syndrome stage iii mycosis fungoides/sezary syndrome stage iv mycosis fungoides/sezary syndrome
fat cell size and overfeeding and etopic study

Conditions: Over Eating

Summary: it has been shown that large fat cells are associated with more risks for insulin resistance and more cardiovascular risk factors such as high cholesterol or triglycerides.

this study will look at fat cell size and how it affects fat deposition, insulin resistance and muscle oxidative capacity. a comparison will be made with the differences between participants with larger versus smaller fat cells in insulin resistance and blood levels of lipids. the study will also determine if characteristics of fat cells and muscle can predict the development of weight gain-induced insulin resistance.

Eligibility criteria:
inclusion criteria: * your body mass index (height to weight ratio) is 22.5 to 32.5 (inclusive). * you are 18-40 years of age. * you are willing to enroll in an 8 week overfeeding study causing a 5-8 % weight gain. * you are willing to eat all your meals from pennington and only meals from pennington for approximately 10 weeks total, even when you are full. prior to overfeeding 2 meals per day will be served at pennington with lunch packed for at least 7 days. after that time participants will receive and eat all (overfeeding) meals at pbrc for 8 weeks. post-overfeeding will consists of weight-maintenance diet for 1 week. all meals will be monitored at pennington. * you are willing to maintain the same level of exercise after enrollment in the study throughout the length of the study. * you are willing to complete nutritional and activity questionnaires. exclusion criteria: * you weight \> 300 lbs * you have a history of cardiovascular disease or diabetes. * you have a fasting blood glucose \> 110 mg/dl. * you have an average screening blood pressure \> 140/90. * you have liver disease. * you have thyroid disease. * have acid reflux * had cancer in the last 5 years (some skin cancers ok) * have hiv * have had an eating disorders * you are pregnant or breastfeeding. * you have gained or lost more than 3kg in the last 3 months * you require chronic use of medications including diuretics, steroids and adrenergic-stimulating agents. * you or a member of your family has a history of blood clots (deep vein thrombosis or pulmonary embolism) * you have poor circulation, history of bypass operation in your legs, blood coagulation disorders, diagnosed peripheral arterial or vascular disease, cramping pain in your leg muscle during exercise or nerve damage to your legs * you have varicose veins (per discretion of md or np) * you have had previous gi surgery, obstructive disease of the gi tract, hyper motility disorder or a history of problems of impairment of the gag reflex. * you have emotional problems such as clinical depression or other diagnosed psychological conditions. * you are claustrophobic. * you have metal objects in your body such as implanted rods or surgical clips or magnetic objects that are incompatible with the mri/mrs. * you smoke or use tobacco products
efficacy and safety of nvp-1203 in patients with acute low back pain

Conditions: Acute Low Back Pain

Summary: the purpose of this study is to evaluate the efficacy and safety nvp-1203 in patients with acute low back pain

this study is a randomized, double-blind, active- and placebo-controlled, parallel, phase ii study to evaluate efficacy and safety of nvp-1203 in patients with acute low back pain

Eligibility criteria:
inclusion criteria: * subjects who have ability to comprehend the contents of study and before participating in trial and have willingness to sign of informed consent in writing * 19 years and older * a patient has symptom of acute low back pain exclusion criteria: * subjects who cannot prohibit anti-inflammatory drug or muscle relaxants during clinical trial * inadequate subject for the clinical trial by the investigator's decision
treatment of atrial fibrillation in the community settings

Conditions: Atrial Arrhythmia; Cardiovascular Diseases

Summary: description of treatment of cardiovascular diseases in community settings in russia

the study will describe different treatment modalities used in management of cardiovascular diseases in community hospital in small town of tarusa in russia. this part of the study will focus on atrial fibrillation and its treatment.

Eligibility criteria:
inclusion criteria: * all patients undergoing direct current cardioversion for atrial fibrillation or flutter exclusion criteria: * none
music for anxiety management in cesarean delivery

Conditions: Pregnancy

Summary: a randomized controlled trial will be conducted to determine examine the effects of music played during cesarean delivery on maternal anxiety and vital signs.

it will tested the hypotheses that there is no difference between the intervention and control groups of pregnant women after the intervention in terms of anxiety and vita lsymptoms.

Eligibility criteria:
inclusion criteria: - aged between 18-35 years, * undergoing cesarean section under spinal anesthesia, * experiencing spontaneous and singleton pregnancy, * with a gestational age greater than 37 weeks, * pregnant individuals who have had at least 4 routine check-ups during pregnancy conducted by a member of the research team, * scheduled for cesarean section (regardless of the number of previous cesarean sections). exclusion criteria: * having high-risk pregnancies such as preeclampsia, early membrane rupture, and placental abruption, • being scheduled for emergency cesarean section for any reason

Keywords: cesarean section music randomize trial
brain activity flow patterns analysis using evoked response potentials in youth with adhd, bipolar disorder, or autism spectrum disorders: a preliminary study

Conditions: Attention Deficit Hyperactivity Disorder; Autism Spectrum Disorder; Bipolar Disorder

Summary: the study aims to evaluate whether or not an eeg (a type of brain scan) is useful in diagnosing youth with either adhd, bpd, asd. youth with adhd, bpd, asd, and healthy controls (without adhd, bpd, and asd) will undergo an eeg, and the results will be analyzed using brain activity flow pattern analysis (bafpa). twenty subjects with each disorder and twenty without any of the disorders under study (controls) will be evaluated. all subjects will be comprehensively assessed with structured diagnostic interviews and neuropsychological testing. all eeg analyses will be conducted under blind conditions. conditional probability and receiver operating characteristic (roc) analyses will examine the diagnostic utility of the eeg scan, using the clinical diagnosis of asd as the gold standard.


Eligibility criteria:
inclusion criteria: * male or female participants between 6 and 17 years of age. * right handedness. * fulfills dsm-iv-tr diagnostic criteria for adhd, bipolar disorder (bpd i, ii, or nos), or asd (autistic disorder, asperger's disorder, or pdd-nos) as established by clinical diagnostic interview and supported by k-sads-e module for respective diagnoses. * subjects and their legal representative must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol. * subjects and their legal representative must be considered reliable. * each subject and his/her authorized legal representative must understand the nature of the study. the subject's authorized legal representative must sign an informed consent document and the subject must sign an informed assent document. exclusion criteria: * investigator and his/her immediate family; defined as the investigator's spouse, parent, child, grandparent, or grandchild. * i.q. \< 85 * history of active seizure disorder (as suggested by eeg suggestive of seizure activity and/or history of seizure in last 1 month) * pregnant or nursing females. * subjects with a medical condition that will either jeopardize subject safety or affect the scientific merit of the study, including: * organic brain disorders * uncorrected hypothyroidism or hyperthyroidism * renal or hepatic impairment. * clinically unstable psychiatric conditions or judged to be at serious suicidal risk * current diagnosis of schizophrenia * history of substance use (except nicotine or caffeine) within past 3 months or urine drug screen positive for substances of abuse * significant sensory deficits such as deafness or blindness.

Keywords: adhd pediatric bipolar disorder autism autism spectrum disorders eeg brain flow analyses
one year clinical evaluation of conservative versus conventional ceramic onlays

Conditions: Tooth Decay

Summary: the aim of present study is to evaluate clinically the fracture liability , marginal adaptation , and patient satisfaction of conservative versus conventional ceramic onlays use e-max press to restore defective restored molar with old restoration or caries. with one or more cusp defect


Eligibility criteria:
inclusion criteria:inclusion criteria: all subjects are required to be: 1-from 18-50 years old, be able to read and sign the informed consent document. 2- have no active periodontal or pulpal diseases, have teeth with good restorations 3- psychologically and physically able to withstand conventional dental procedures 4- patients with teeth problems indicated for onlay restoration: 1. decayed teeth 2. teeth restored with defected filling restorations 3. teeth with occlusal defect 5- able to return for follow-up examinations and evaluation exclusion criteria 1. patient less than 18 or more than 50 years 2. patient with active resistant periodontal diseases 3. patients with poor oral hygiene and uncooperative patients 4. pregnant women 5. patients in the growth stage with partially erupted teeth 6. psychiatric problems or unrealistic expectations 7. lack of opposing dentition in the area of interest - -
bone ultrasonic scanner (buss) clinical optimization study

Conditions: Osteoporosis

Summary: the aim of this clinical study using bone ultrasonic scanner (buss) is to obtain clinical data which will help to optimize the buss examination procedure and its diagnostic algorithms for assessment of bone conditions.

the specific aims of this clinical study are: 1. to optimize the data collection technique and establish an examination procedure; 2. to collect data necessary for assessing the performance of buss sensors; 3. to evaluate the probe ergonomic design and participant tolerance to probe application; 4. to assess the clinical suitability of the software interface in data collection; 5. to adjust the buss diagnostic algorithms using dual-energy x-ray absorptiometry (dexa) data as a "gold" standard in osteoporosis detection and characterization; 6. to evaluate buss performance including ease of use and consistency.

Eligibility criteria:
inclusion criteria: any race or ethnical group dexa examination scheduled within next two weeks or dexa examination was completed within the last six months adn dexa results are available exclusion criteria: open wounds or rashes on the tibial testing area active skin infection recent tibia surgery abnormal tibia anatomy current or previous tibial fracture body mass index \>34.9 hyperparathyroidism or hypoparathyroidism within 5 years osteitis deformans renal osteodystrophy osteomalacia stroke with total or partial paralysis with residual disability lasting more than 3 months current or recent (within past 6 months) use of bone-active drugs drugs under research protocols chronic use of over the counter antacids -

Keywords: osteoporosis, bone fracture risk, bone ultrasonometry
first optical coherence microscopy in dermato-oncology

Conditions: Skin Cancer

Summary: octav is a medical device class i, not ce marked, based on a new technique for high-resolution imager (cell) internal microstructures of all types of biological tissues in vivo or ex vivo, to a depth of penetration 800 .mu.m. it allows to explore the epidermis, the dermo-epidermal junction and middle dermis in a totally non-invasive (direct contact with the tissue without sampling).

at the coming of the patient in dermatology for resection / biopsy of the tumor (usual practice), for the study, an image of the tumor will be performed with the octav device (about 5 minutes) for the study. then, according to usual practice, resection / biopsy will be performed. this study aims to validate the clinical relevance of this device to characterize the 3 main skin cancers and to obtain the necessary data for the implementation of future clinical trials.

Eligibility criteria:
for patient inclusion criteria: * patient with a cutaneous lesion suspicious for melanoma, basal cell carcinoma, squamous cell carcinoma, requiring a surgical excision * consent form signed * major patient exclusion criteria: * allergy or intolerance to immersion oil (used for microscopy) * if female, pregnant or breast-feeding * patient unable to stand still for 60 seconds * skin lesions located near patient eyes (\<3 cm) for control group inclusion criteria: * aged between 18 to 40 years * consent form signed * patient of the dermatology department with non-pathological forearm skin exclusion criteria: * allergy or intolerance to immersion oil (used for microscopy) * if female, pregnant or breast-feeding * patient unable to stand still for 60 seconds

Keywords: optical biopsy skin cancer diagnostic performance
efficacy and safety of valsartan 160mg and rosuvastatin 20mg in patients with hypertension and hyperlipidemia

Conditions: Hypertension,; Hyperlipidemia

Summary: this study aims to evaluate the efficacy and safety of the coadministration of valsartan (diovan®) 160mg and rosuvastatin (crestor®) 20mg in comparison to each component administered alone in patients with hypertension and hyperlipidemia.


Eligibility criteria:
inclusion criteria: 1. patient aged 20-80 years who has hypertension and hyperlipidemia 2. patient who has a hypertension 3. patient who has a hyperlipidemia according to ncep-atp iii guideline(2004) 4. patient who signed the informed consent form after receiving an explanation on the purpose, methods, and effect of the study exclusion criteria: 1. if blood pressure and fasting serum lipid level measured at screening and visit 2 (0 week) satisfy the following criteria 1) sitsbp≥180mmhg or sitdbp≥110mmhg (for high risk group, sitsbp≥ 160mmhg or sitdbp ≥100mmhg ) 2) ldl-c\>250mg/dl , or tg≥ 400mg/dl 2. if sitsbp difference between the right and left arms \>20mmhg or sitdbp difference between the right and left arms \> 10mmhg at screening 3. when blood pressure is repeatedly measured from the selected arm at screening, if sitsbp difference ≥ 20mmhg or sitdbp difference ≥10mmhg 4. patient with orthostatic hypotension accompanying symptoms at screening (decrease in sitdbp ≥10mmhg or decrease in sitsbp ≥ 20mmhg )